Philips Stock Over‑valued: Why Investors Must Reassess the Health‑Tech Giant’s P/E Ratio
Philips’ high P/E and lack of breakthrough growth leave its health‑tech giant status a speculative gamble, urging investors to reassess its realistic valuation.
3 minutes to read




